At the onset of acute GvHD after allogeneic hematopoietic cell transplantation (HCT), symptoms and signs are not severe in most patients. The subsequent development of severe acute GvHD despite treatment with high-dose corticosteroids, however, is associated with an increased risk of non-relapse mortality. 1 Skin biopsies are frequently obtained to verify or establish a diagnosis of acute GvHD. The degree of apoptosis or epidermal damage based on evaluation of skin sections by routine hematoxylin and eosin staining or immunostaining for lymphoid markers has not provided useful predictive information on eventual outcomes in patients with acute GvHD. In contrast, Nishiwaki et al. 2 recently demonstrated a higher content of dermal interface macrophages in sections from the skin biopsies taken soon after the onset of acute GvHD was significantly correlated with steroid unresponsiveness and increased mortality. Acceptance of a biomarker that predicts outcome requires confirmation by a second independent study obtained from a separate cohort of patients. Therefore, we sought to determine whether the findings of Nishiwaki et al. 2 could be replicated in a nested case-control study of patients who had skin biopsies shortly after the onset of acute GvHD at the Fred Hutchinson Cancer Research Center.
In a case-control study, we selected patients who had (1) HCT after myeloablative conditioning between 2000 and 2009, (2) acute GvHD involving the skin, (3) a skin biopsy taken o7 days after the diagnosis of acute GvHD and o 7 days before or after the onset of treatment for acute GvHD and (4) signed written informed consent allowing the use of medical records and biospecimens for research. Cases were defined as patients who had non-relapse mortality within 1 year, whereas controls were defined as patients surviving without recurrent malignancy for at least 1 year after the onset of treatment for acute GvHD. The Institutional Review Board approved the study. Figure 1c ). All the dermal macrophages at the epidermal-dermal interface throughout the papillary dermis and within the peri-appendigeal and perivascular regions were assessed. We employed this method because of the difficulty in enumerating overlapping individual macrophages when heavy infiltration was present. This method also avoided the bias that could be introduced when the analysis is limited to a small segment of epidermis subjectively selected to be the most heavily infiltrated. Coded histological sections were assessed and graded according to the intensity of macrophage infiltration by an expert pathologist (HMS) who had no information regarding survival or other clinical details.
Results of the previous study 2 showed that the proportion of patients with grade 3 infiltration was 9/21 (43%) among cases and 2/25 (8%) among controls. The present study was designed to test the null hypothesis that the proportion of patients with grade 3 infiltration is identical in cases and controls. With a 1:1 distribution of cases and controls,~25% of the samples would be expected to have grade 3 infiltration. From 2000 through 2009, a total of 200 patients (75 cases and 125 controls) fulfilled the eligibility criteria. A cohort of 56 cases and 56 controls was estimated to provide 95% power to reject the null hypothesis in favor of the alternative of 40% among cases versus 10% among controls in the proportions of samples with grade 3 infiltration.
The study cohort included 55 randomly selected cases and 56 randomly selected controls. The median time from transplantation to biopsy was 20 days (range, 6-101). Seven (6%) patients had peak stage 1 skin GvHD, 22 (20%) had peak stage 2 skin GvHD, 77 (69%) had peak stage 3 skin GvHD and 5 (5%) had peak stage 4 skin GvHD, with no statistically significant difference between cases and controls (P = 0.40, Wilcoxon test). The pathologist assessed the entire biopsy for degree of macrophage infiltration and did not rely on a subjective assessment of the segment of epidermis with the heaviest infiltrate. This approach avoided the problem of counting overlapping cells. The study pathologist noted striking differences across the grades of macrophage infiltration (Figure 1 ). Higher grades of macrophage infiltration were associated with higher peak severity of skin GvHD (P = 0.03, Kruskal-Wallis test) (data not shown). Grade 3 macrophage infiltration was observed in 27 of the 111 (24%) individuals tested, including 18 of 55 (33%) cases and 9 of 56 (16%) controls (odds ratio, 2.54; 95% confidence interval, 1.0-6.3, P = 0.041) ( Table 1) . The sensitivity was 33% (18/55) and specificity was 84% (47/56). On the basis of proportions observed in the cases and controls, we would have expected grade 3 infiltration in~25 patients who died (18/55 × 75) and~20 patients who survived (9/56 × 125) in the original cohort. The positive predictive value is 56% (25/(25+20)). In a sensitivity analysis, grade 2 or 3 macrophage infiltration was observed in 42/55 (76%) cases and in 30/56 (53%) controls (odds ratio, 2.80; 95% confidence interval 1.2-6.3; P = 0.012). The corresponding sensitivity, specificity and positive predictive values are 76%, 46% and 46%, respectively. Therefore, the odds ratio and positive predictive value in comparing grade 2-3 versus grade 0-1 infiltration were similar to those for grade 3 versus grade 0-2 infiltration, although the sensitivity and specificity differed, as would be expected.
These results are consistent with the previous report. 2 Although we observed a statistically significant association between grade 3 infiltration and risk of death, the positive predictive value of this test is not sufficient for purposes of determining the intensity of initial immunosuppressive treatment for acute GvHD involving the skin. Therefore, routine assessment of macrophage infiltration in skin specimens is not recommended as a guide to making clinical decisions. Additional predictive factors or combinations of existing predictive factors are needed for more accurate stratification of treatment intensity. 3 Heavy macrophage infiltration in human skin biopsies after the onset of acute GvHD in humans could represent a physiological control or regulatory mechanism that reflects the severity of the immunological attack by donor T cells but is not sufficient to prevent the increased risk of death associated with severe GvHD. Alternatively, heavy macrophage infiltration could represent a component of the inflammatory response that contributes to GvHD. Previous experimental studies have shown that depletion of recipient macrophage populations in vivo by blocking CSF-1 binding to its receptor before allogeneic HCT exacerbated GvHD, whereas expansion of recipient macrophage populations by administration of CSF-1 before HCT attenuated GvHD. 4 These results suggest that the recipient macrophages inhibit the development of GvHD. Other investigators have shown more recently that blocking CSF-1 binding to its receptor beginning on day 7 after HCT depleted donor macrophages in vivo and attenuated cutaneous chronic GvHD, whereas administration of CSF-1 from days 14 to 19 after HCT expanded donor macrophages in vivo and exacerbated cutaneous chronic GvHD. 5 The differences in results could reflect the timing of CSF-1 administration, the strain combinations tested or the variation in the persistence of recipient macrophages after HCT.
The biopsies in our study were done at a median of 20 days after HCT. Previous work has clearly shown that cutaneous macrophages are derived predominantly from the recipient at this time after HCT, even with full-intensity conditioning and in the presence of GvHD. 6 Further work is needed to clarify whether heavy macrophage infiltration exacerbates or attenuates the severity of GvHD in humans. The association of macrophage infiltration with the risk of mortality is not sufficiently strong to allow the clinical use of this biomarker as an independent prognostic indicator. This biomarker might merit consideration as a prognostic component in combination with other risk factors. Grade 3  18  9  27  Grade 1 and 2  37  47  84  Total  55  56  111 
